MLN1202 meets Phase II atherosclerosis endpoint

Millennium (MLNM) said MLN1202 met the primary endpoint of a significant reduction in C-reactive protein (CRP) levels vs. placebo in a U.S. Phase II trial in 108 patients at high risk for atherosclero...